<DOC>
	<DOCNO>NCT02458768</DOCNO>
	<brief_summary>The objective study demonstrate non-inferiority IVFM HP Inj . evaluate efficacy versus Menopur® Inj . infertility woman undergo vitro fertilization embryo transfer ( IVF-ET ) among assisted reproductive technology .</brief_summary>
	<brief_title>Multicenter , Randomized , Open Label , Parallel Study Evaluate Efficacy &amp; Safety IVF-M HP Inj . vs. Menopur® Inj .</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility , Female</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<criteria>Adult woman 20 39 year age screen Subjects mean menstrual cycle day ( MCD ) 25 35 day Subjects Follicle Stimulating Hormone ( FSH ) concentration screen exceed upper limit normal range ( ULN ) Those diagnosed infertility due least one follow cause infertility Fallopian tubal factor Infertility due unknown cause Male infertility Complex factor Subjects normal ovarian uterine function Subjects 3 time prior experience vitro fertilization Subjects neither administered clomiphene citrate within 30 day gonadotropin within 14 day IP administration day Subjects inform objective , method effect etc . clinical study sign informed consent form Subjects contraindicate pregnancy Subjects BMI &gt; 30 ( BMI ; kg/m2 ) Subjects diagnose polycystic ovary syndrome ( PCOS ) Subjects experienced previously least Grade 4 ovarian hyperstimulation syndrome ( OHSS ) Subjects poor response gonadotropin ( According Bologna criteria* ) *At least two follow three feature must present : ① Advanced maternal age ( &gt; =40 year ) risk factor Poor Ovarian Response ( POR ) ② A previous POR ( &lt; =3 oocyte conventional stimulation protocol ) ③ An abnormal ovarian reserve test ( i.e . Antral follicle Count ( AFC ) &lt; 5 follicle AntiMullerian hormone ( AMH ) &lt; 0.5 ng/ml ) Those abnormal metrorrhagia due unknown cause screen Subjects submucosal uterine leiomyoma Subjects least borderline ovarian tumor Subjects history malignant tumor breast Subjects hydrosalpinx remove operation Subjects Thyroid Stimulating Hormone ( TSH ) level normal range screen Subjects history malignant tumor within 5 year prior screen Subjects severe disease potentially affect study pituitary insufficiency upon investigator 's judgment ( e.g. , heart failure , renal failure , hepatic failure adrenal insufficiency etc . ) Subject HIV syphilispositive result screen Subjects psychiatric disorder screen fail understanding objective method clinical study Subject diagnose alcohol drug abuse within 3 month prior screen Subjects history hypersensitivity investigational product clinical study Subjects current history thromboembolism vein artery Subjects history genetic problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption etc . Subjects participate another clinical study relate drug administration enrollment study participate another clinical study within 3 month prior enrollment study Others include subject consider difficult conduct clinical study upon principal investigator 's judgment</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>